Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.

A. Abudayyeh; A. Esmail; A. Kaseb; J. Xu; K. Abboud; G. Umoru; M. Abdelrahim

doi:10.1016/j.hpb.2023.07.252

Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.

A. Abudayyeh, A. Esmail, A. Kaseb, J. Xu, K. Abboud, G. Umoru, M. Abdelrahim

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S321
Journal	HPB
Volume	25
DOIs	https://doi.org/10.1016/j.hpb.2023.07.252
State	Published - 2023

Access to Document

10.1016/j.hpb.2023.07.252

https://www.sciencedirect.com/science/article/pii/S1365182X23011474

Cite this

Abudayyeh, A., Esmail, A., Kaseb, A., Xu, J., Abboud, K., Umoru, G., & Abdelrahim, M. (2023). Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France. HPB, 25, S321. https://doi.org/10.1016/j.hpb.2023.07.252

Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France. / Abudayyeh, A.; Esmail, A.; Kaseb, A. et al.
In: HPB, Vol. 25, 2023, p. S321.

Research output: Contribution to journal › Article › peer-review

Abudayyeh, A, Esmail, A, Kaseb, A, Xu, J, Abboud, K, Umoru, G & Abdelrahim, M 2023, 'Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.', HPB, vol. 25, pp. S321. https://doi.org/10.1016/j.hpb.2023.07.252

Abudayyeh A, Esmail A, Kaseb A, Xu J, Abboud K, Umoru G et al. Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France. HPB. 2023;25:S321. doi: 10.1016/j.hpb.2023.07.252

@article{490113d880f14e18ac4d8302253bb8cf,

title = "Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.",

author = "A. Abudayyeh and A. Esmail and A. Kaseb and J. Xu and K. Abboud and G. Umoru and M. Abdelrahim",

year = "2023",

doi = "10.1016/j.hpb.2023.07.252",

language = "English (US)",

volume = "25",

pages = "S321",

journal = "HPB",

issn = "1365-182X",

publisher = "Wiley",

}

TY - JOUR

T1 - Outcomes with Second-line Treatment Following First Line Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma

T2 - Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.

AU - Abudayyeh, A.

AU - Esmail, A.

AU - Kaseb, A.

AU - Xu, J.

AU - Abboud, K.

AU - Umoru, G.

AU - Abdelrahim, M.

PY - 2023

Y1 - 2023

U2 - 10.1016/j.hpb.2023.07.252

DO - 10.1016/j.hpb.2023.07.252

M3 - Article

SN - 1365-182X

VL - 25

SP - S321

JO - HPB

JF - HPB

ER -